Milica Mitrevski

Rome, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

European Medicines Agency (EMA) commentary on EMA/CHMP Guideline on allergen products development for immunotherapy and allergy diagnosis in moderate to low-sized study populations.

European Medicines Agency (EMA) commentary on EMA/CHMP Guideline on allergen products development for immunotherapy and allergy diagnosis in moderate to low-sized study populations.

Journal: British journal of clinical pharmacology
Published: February 24, 2025

Correction to: Imaging of Bronchial Pathology in Antibody Deficiency: Data from the European Chest CT Group.

Correction to: Imaging of Bronchial Pathology in Antibody Deficiency: Data from the European Chest CT Group.

Journal: Journal of clinical immunology
Published: March 25, 2019

DEC1/STRA13 is a key negative regulator of activation-induced proliferation of human B cells highly expressed in anergic cells.

DEC1/STRA13 is a key negative regulator of activation-induced proliferation of human B cells highly expressed in anergic cells.

Journal: Immunology letters
Published: October 25, 2017

Imaging of Bronchial Pathology in Antibody Deficiency: Data from the European Chest CT Group.

Imaging of Bronchial Pathology in Antibody Deficiency: Data from the European Chest CT Group.

Journal: Journal of clinical immunology
Published: July 16, 2017

Reversion of anergy signatures in clonal CD21low B cells of mixed cryoglobulinemia after clearance of HCV viremia.

Reversion of anergy signatures in clonal CD21low B cells of mixed cryoglobulinemia after clearance of HCV viremia.

Journal: Blood
Published: March 01, 2017

Modulatory Effects of Antibody Replacement Therapy to Innate and Adaptive Immune Cells.

Modulatory Effects of Antibody Replacement Therapy to Innate and Adaptive Immune Cells.

Journal: Frontiers in immunology
Published: March 01, 2017

Efficacy and safety of long-term treatment with low-dose rituximab for relapsing mixed cryoglobulinemia vasculitis.

Efficacy and safety of long-term treatment with low-dose rituximab for relapsing mixed cryoglobulinemia vasculitis.

Journal: Clinical rheumatology
Published: December 30, 2016

Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia.

Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia.

Journal: Hepatology (Baltimore, Md.)
Published: April 02, 2016

Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review.

Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review.

Journal: Autoimmunity reviews
Published: May 15, 2015

Hepatitis B virus causes mixed cryoglobulinaemia by driving clonal expansion of innate B-cells producing a VH1-69-encoded antibody.

Hepatitis B virus causes mixed cryoglobulinaemia by driving clonal expansion of innate B-cells producing a VH1-69-encoded antibody.

Journal: Clinical and experimental rheumatology
Published: April 23, 2015

Intravenous immunoglobulin replacement therapy in common variable immunodeficiency induces B cell depletion through differentiation into apoptosis-prone CD21(low) B cells.

Intravenous immunoglobulin replacement therapy in common variable immunodeficiency induces B cell depletion through differentiation into apoptosis-prone CD21(low) B cells.

Journal: Immunologic research
Published: November 20, 2014

Intravenous Immunoglobulin and Immunomodulation of B-Cell - in vitro and in vivo Effects.

Intravenous Immunoglobulin and Immunomodulation of B-Cell - in vitro and in vivo Effects.

Journal: Frontiers in immunology
Published: October 27, 2014
Showing 1-12 of 13

Last Updated: 09/26/2026